Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Eli Lilly is taking the HRSA to court after the latter allegedly blocked the pharma's plan on the manner of offering ...
Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...
Johnson and Johnson Nov. 12 filed a lawsuit against the Department of Health and Human Services and the Health Resources and ...
The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...
Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...
Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...
Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the ...
Leidos announced a new contract to modernize the Organ Procurement and Transplant Network (OPTN), a critical system that delivers vital organ transplant information to patients, donors, and healthcare ...
Premier alleges the Health Resources and Services Administration lacks authority to enforce a policy restricting how 340B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback